Overexpression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer by Saghaeian Jazi, M. et al.
ORIGINAL ARTICLE
Overexpression of the non-coding SOX2OT variants 4 and 7
in lung tumors suggests an oncogenic role in lung cancer
Marie Saghaeian Jazi1 & Nader Mansour Samaei2,3 & Mostafa Ghanei4 &
Mohammad Behgam Shadmehr5 & Seyed Javad Mowla6
Received: 2 December 2015 /Accepted: 20 January 2016 /Published online: 4 February 2016
# International Society of Oncology and BioMarkers (ISOBM) 2016
Abstract Despite the advances in cancer therapy, lung cancer
still remains the most leading cause of cancer death world-
wide. The long non-coding RNAs (lncRNAs) are recently
introduced as novel regulators of human cancers. SOX2 over-
lapping transcript (SOX2OT) is a cancer-associated lncRNA
gene that encodes different alternatively spliced transcripts.
Here, we investigated the alterations in the preferential expres-
sion of different SOX2OTs in twenty non-small cell lung can-
cer (NSCLC) patients by real-time quantitative reverse tran-
scription PCR (qRT-PCR) method. We observed preferential
expression of SOX2OT4 and SOX2OT7 in lung tumor tissues.
The quantitative gene expression analysis revealed that >30 %
of NSCLC tumors express SOX2OT4 (mean=7.6 times) and
SOX2OT7 (mean=5.9 times) more than normal tissues, with
higher expression in squamous cell carcinoma. Further, we
observed overexpression of pluripotency-associated transcrip-
tion factor, SOX2 in 47 % of our samples concordant with
SOX2OT (R = 0.62, P value <0.05). Overexpression of
OCT4A gene was also observed in 36.8 % of tumor tissues.
Then, we investigated the effects of SOX2OT suppression in
lung adenocarcinoma cell line, by means of RNAi. Cell char-
acteristics of colony formation, apoptosis, 2-D mobility, and
cell cycle progression were measured in control and treated
A549 cells. The SOX2OT knockdown significantly reduced
the colony formation ability of cancer cells; however, no al-
terations in the rate of apoptosis were detected. On the other
hand, SOX2OT-suppressed cells had elevated accumulation in
G2/M phase of cell cycle and exhibited limited mobility.
Altogether, our findings support a potential oncogenic role
for SOX2OT in non-small cell lung cancer tumor genesis and
SOX2OT seems a promising therapeutic candidate for
NSCLC.
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Introduction
Globally, lung cancer is the most common cancer that harbors
the highest mortality and morbidity rate among all kinds of
cancers worldwide [1–3]. Recent advances in experimental
oncology and molecular medicine have provided targeted
therapies regarding the genetic alterations in lung cancer.
The genetic alterations in EGFR, KRAS, and ALK genes are
the best examples of targeted oncogenes in lung cancer ther-
apy [4, 5], whereas the non-protein coding regulators are
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underestimated in this context. Most of the human genome
(about 98 %) is consisted of non-coding genes that are almost
transcribed into ribonucleic acids [6–8]. Subsequently, emerg-
ing roles are expected for long non-coding RNAs (lncRNAs)
in the diagnosis, prevention, and treatment of lung carcinoma
[9–14] like other cancers [15].
SOX2 overlapping transcript (SOX2OT) is a long non-coding
RNA gene located in chr3q26.33, which is frequently amplified
in lung cancer tissues [16, 17]. It encodes different transcript
variants with alternative splicing in a tissue-specific manner
[18, 19]. However, it cannot encode any protein sequence [20].
Recently, it has been reported that SOX2OT is
overexpressed in breast, hepatocarcinoma, and esophagus tu-
mor tissues [21–24] and also in lung carcinoma that is associ-
ated with poor survival in NSCLC patients [25].
In the present study, first of all, we screened the lung tissue-
specific expression of different SOX2OTs, and then the ex-
pression alterations in adenocarcinoma (AC) and squamous
cell carcinoma (SCC) tumors of NSCLC patients (n=20)
were investigated. It has been reported that SOX2 and
OCT4, two of the pluripotency key factors, role as oncogenes
in lung tumor genesis and progression [26]. Considering the
previously reported association of SOX2OTwith pluripotency
[18, 23], we focused the expression of SOX2 and OCT4A
transcription factors synchronously. To study the function of
SOX2OT in lung cancer, we explored the cellular response of
lung adenocarcinoma cell line (A549) to SOX2OTsuppression
in vitro. For this purpose, a series of experiments including
colony formation assay, wound closure assay, apoptosis, and




Twenty NSCLC surgical sample pairs (tumor and apparently
normal tissues from the same patients) were provided by
Tracheal Diseases Research Center, National Research
Institute of Tuberculosis and Lung Diseases (NRITLD),
Shahid Beheshti University of Medical Sciences, Tehran,
Iran. The clinico-pathological information of patients includ-
ing the age, tumor subtypes, tumor stage and score (according
TNM Classification) is provided in Table 1. The research
ethics committee of NRITLD and Golestan University of
Medical Sciences (code: 92041130) approved the experimen-
tal procedure. A signed informed consent form was also ob-
tained from each patient. Small surgical pieces of tumor and
non-tumor tissue samples from the same lung lobe of patients
were put in a RNase-free Eppendorf tube and immediately
snap-frozen in liquid nitrogen, and stored in −80 °C for later
RNA extraction.
Cell culture and transfection
Two cell lines of human lung adenocarcinoma cancer cell line,
A549 and glioblastoma multiform cell line, U-87 MG were
obtained from Pasture institute (Tehran, Iran). Cells were cul-
tured in RPMI1640 medium (Invitrogen, Gaithersburg, MD)
supplemented with 10% fetal bovine serum (FBS; Invitrogen,
Gaithersburg, MD), and 100 IU penicillin 100 μg streptomy-
cin per ml (Invitrogen, Gaithersburg, MD), and cultivated in a
98 % humidified and 5 % CO2 incubator.
A g e n e r a l S O X 2O T - s p e c i f i c s i R NA ( 5 ′ -
GGAGAUUGUGACCUGGCUU-3′) capable of hitting both
variants 4 and 7 was designed and synthesized by Bioneer Inc
(Daejeon, Korea). For siRNA transfection, 5×105 cells were
seeded in six-well tissue culture plates. After 24 h, the cells
(about 80 % confluent) were transfected with scramble
(SantaCruse, s-c37007), and SOX2OT (50 or 100 nM)
siRNAs, using Lipofectamine 2000 and according to the man-
ufacturers protocol. The efficiency of siRNA delivery was
monitored by fluorescent inverted microscope (Nikon, Ti-U
model) in cells transfected with FITC-siRNA (Fig. 3a). Forty
eight hours later, the cells were harvested for RNA extraction
or functional assays.
Colony formation assay
The colony formation potential was measured by routine moni-
toring of treated cells for 12 days. Briefly, about 200 cells were
seeded in a six-well tissue culture plate, before being transfected
by siRNAs, 24 h later. Then, transfected cells were incubated in
CO2 incubator and completemediumwhichwere renewed every
3 days. The colonies were washed with PBS and fixed by 4 %
paraformaldehyde at room temperature. Crystal violet (0.1 %W/
V) in PBS was used to stain the colonies for 10 min. Colonies
then were washed by PBS and were imaged by digital camera or
microscopically. Colonies consisting <50 cells or smaller than
1 mm were excluded from counting. Images were analyzed by
ImageJ 1.4 software colony count tool.
Flow cytometry analysis
The siRNA-treated cells were washed with PBS, before being
harvested. The annexin V/PI (Sigma-Aldrich) staining was per-
formed for cells according to the manufacturer’s instruction.
Then, the stained cells were studied by Partec flow cytometry
instrument (Partec GmbH, Münster, Germany). The percentage
of annexin Vand propodium iodide positive cells were measured
for early and late apoptosis estimation.
For the cell cycle evaluation, treated cells were washed
with PBS and harvested for DNA content staining, 48 h after
transfection. Cells were then fixed in cold ethanol (70 %) for
1 h in −20 °C, then were permeabilized with triton X −100
(0.1 %). The RNA content of cells was depleted with 30 min
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RNaseI (Fermentase) treatment (10 μl/ml) in 37 °C tempera-
ture. Then, the cells were stained with Propodium Iodide
(10 μg/ml), and the percent of cell population in different
phase of cell cycle was analyzed with flow cytometry.
Wound closure assay
The two-dimensional cell migration were measured by per-
cent of gap area in a wounded region. The number of 5×105
Cells were seeded in a six-well tissue culture plate and were
transfected with siRNA. Twenty four hours later, the culture
medium was changed with a 0.5 % serum one to minimize the
cell proliferation. The cells were almost confluent at 48 h after
transfection when a sterile tip was used to scratch the center of
the well. The wounded region was imaged by light microsco-
py immediately (0 h) and 24 h later. For same fields of images,
the wound edges were found and the gap area was calculated
by ImageJ v1.4 software. The percentage of wound closure
was calculated as (gap area in 24 h/gap area in 0 h)×100.
Gene expression measurement
The total cellular RNA was extracted using Trizol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s pro-
tocol. Complementary DNA was synthesized using revert aid
first strand cDNA synthesis kit (Thermo Fisher Scientific, Inc)
following by DNaseI (Thermo Fisher Scientific, Inc) treatment.
Quantitative measurement of gene expression was carried
out by SYBR green real-time PCR kit (Thermo Fisher
Scientific, Inc) with specific primers listed in Table 2; for
SOX2 [GeneBank: NM_003106.3], SOX2OT [GeneBank:
NR_004053.3, NR_075089.1, NR_075090.1, KF981435,
and KJ415055], OCT4A [GeneBank: NM_002701.4], and
GAPDH [GeneBank: NM_002046.3].
Thermal cycling was performed in ABI system 7300
(Applied Biosystems, Foster City, CA) scheduled to 95 °C
for 10 min (enzyme activation), 40 cycles of 95 °C for 10 s
(denaturing), 58 °C for 15 s (annealing), and 72 °C for 30 s
(extension). Then, final dissociation curve analysis was per-
formed to ensure the specific PCR product amplification.
The gene expression of tumor tissues was normalized to
paired normal tissue of same patient and then the quantitative
gene expression fold changes were calculated by the 2-ΔΔCt
method, considering GAPDH as housekeeping gene.
Statistical analysis
The measurements were carried out in experimental replicates
to decrease the artificial error. The SPSS v22 software was
used to analyze data statistically. For statistical tests, 95 %
confidence interval and P value ≥0.05 were considered. For
gene expression results, the mean ±SE of calculated fold
changes was compared between SOX2OT:siRNA and
Scrambeled:siRNA or between tumor and normal tissues as
well as tumor sub-types (squamous and adenocarcinoma) and
stages (TNM stages A and B). Student’s t test (two tailed) was
performed for each gene separately to analyze the tissue gene
expression results. The one-way ANOVA and Dunnet’s test
were used to compare means of measurements in treated cells
to control. The correlation coefficient of gene expression was
measured by the Spearman’s rho test.
Results
Differential expression of SOX2OT-spliced variants
in lung tumor tissue samples
Using reverse-transcription PCR (RT-PCR), we initially exam-
ined the expression pattern of newly identified human SOX2OT-
spliced variants (transcripts 1–8) in five lung tumor tissue sam-
ples, with specific primers for each variant (Table 2). A schematic
Table 1 The clinicopathological
description of lung cancer patients Patients (N, %) Age Histology (N, %) Stage (N, %) Tumor score (N, %)
Female (5, 15 %) 60 AC (3, 60 %) I (1, 20 %) T1 (1, 20 %)
II (2, 40 %) T2 (2, 40 %)
SCC (2, 40 %) III (1, 20 %) T3 (1, 20 %)
IV (1, 20 %) T4 (1, 20 %)
Male (15, 85 %) 56.6 AC (11, 73.3 %) I (3, 20 %) T1 (2, 13.3 %)
II (8, 53.3 %) T2 (7, 46.6 %)
SCC (4, 26.6 %) III (3, 20 %) T3 (4, 26.6 %)
IV (1, 6.6 %) T4 (2, 13.3 %)
Total 57.16 AC (14, 70 %) I (4, 20 %) T1 (3, 15 %)
II (10, 50 %) T2 (9, 45 %)
SCC (6, 30 %) III (4, 20 %) T3 (5, 25 %)
IV (2, 10 %) T4 (3, 15 %)
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picture of different spliced variants of SOX2OT and the location
of forward and reverse primers for specific detection of each
variant is provided in Fig. 1b.Using theses primers, we examined
a potential expression of SOX2OT variants in lung tumor surgical
specimens. A glioblastoma multiform cell line, U-87 MG, was
utilized as a positive control to compare the expression pattern of
the variants in two samples. As it is shown in Fig. 1a, no or very
low expression was observed for SOX2OT transcripts 5, 6, and 8.
However, variant 7 showed a moderately high and variant 4
presented a significantly high level of expression in lung tumors.
The expression pattern was somehow different from that of U-87
MG glioblastoma cell line which was used as a positive control.
The SOX2OT variants 4–8 were expressed in U-87 MG cells,
with highest expression for variants 4 and 5. The expression of
distal SOX2OT variants 2 and 3 were not observed in neither
NSCLC nor U-87 MG; however, SOX2OT1 was the only distal
Table 2 The specific primer
sequences and PCR product
length
Primer sequences Gene Product (bps)
F1:TCTGTTCAGTATTTGGAAGAAAG;R1:GCAGAGATTATCCGATTTGG SOX2OT4 389
F1; R2: ACATTATTTCTAAGTTGGATATGTC SOX2OT5 398
F1; R3: CATTATTTCTAAGTTGGATTGGA SOX2OT6 111
F1; R4: GCTTGGACCCGCGTG SOX2OT7 104
F2: TTCAGAAACTTATCAAGAGGTTC; R4 SOX2OT8 168
F3:TACAGCATGTCCTACTCGCAG;R5:GAGGAAGAGGTAACCACAGGG SOX2 110
F4:TTCGCAAGCCCTCATTTCAC; R6:CGAGAAGGCGAAATCCGAAG OCT4A 308
F5:GAGCGAGATCCCTCCAAAAT; R7:GGCTGTTGTCATACTTCTCATG GAPDH 196
Fig. 1 The specific expression of
different SOX2OTs (variants 4, 5,
6, 7, and 8) in lung tumor. a The
expression of SOX2OTs in lung
tumor was checked by RT-PCR.
The U-87 MG glioblastoma cell
line was used as positive control
and no RT indicates negative
control. b The schematic
presentation of SOX2OT gene and
its transcripts. The primers and
siRNA target sites are indicated
by arrows. Asterisk indicates the
non-refseq transcripts
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SOX2OT transcript in U-87 MG glioblastoma cell line (data not
shown).
Upregulation of SOX2OT transcripts 4 and 7 in lung
tumor tissues
The relative expression of two most abundantly expressed
SOX2OT variants (transcripts 4 and 7) were measured in lung
tumor tissues of adenocarcinoma and squamous cell carcino-
ma (n=20) by qRT-PCR. The data were normalized to sam-
ples from paired apparently normal lung tissues obtained from
same patients (n=20).
Our data revealed that SOX2OT variants 4 and 7 were up-
regulated around six times in lung tumor tissues, compared to
their non-tumor counterparts (Fig. 2a). However, as shown
(Fig. 2a and supplementary figure 1), the SOX2OT gene ex-
pression level was variable in different tumors. A closer look
at expression of variants in each sample demonstrated that
SOX2OT7 was upregulated in 36.8 % and SOX2OT4 in
31.57 % of lung tumor tissues (Table 3). Furthermore, when
data was re-examined according to the cancer subtypes, it was
noticed that upregulation of SOX2OT4 is significantly higher
in squamous cell lung carcinoma rather than adenocarcinoma
subtype. We found higher expression level for SOX2OT7 in
squamous cell carcinoma but the value was not significant
(Fig. 2b). However, the overexpression of SOX2OT transcripts
was not significantly different in different tumor sizes and
early vs. metastatic tumors, considering the TNM stages (data
not shown).
Concomitant upregulation of SOX2 with SOX2OT in lung
tumor tissues
It is assumed that SOX2OT regulates pluripotency
through controlling SOX2 expression. In order to inves-
tigate a possible association between the expressions of
the genes in lung tumor tissues, we explored the expres-
sion alteration of SOX2 and SOX2OT genes in tumor vs.
non-tumor samples. The expression of OCT4A was also
examined in each sample as a control. Our data re-
vealed that SOX2 was upregulated in tumor samples,
as the same level of SOX2OT variants (in 47 % of the
samples, about six folds), with higher expression in
squamous cell carcinomas, compared to adenocarcinoma
(Fig. 2 and Table 3). We also observed an upregulation
for OCT4A (in 36.8 % of the samples, more than two-
fold increase) in lung tumor samples, compared to ap-
parently normal tissues obtained from the same patients.
However, the relative upregulation was not different in
cancer subtypes.
The Spearman’s rho correlation was calculated for SOX2,
SOX2OT variants 4 and 7, and OCT4A expression in our lung
tissue samples. As was expected, the expression of SOX2OT
variants 7 and 4 (R=0.8, P value <0.005) and pluripotency
genes SOX2 and OCT4A (R=0.55, P value <0.05) were sig-
nificantly correlated with each other. We also found that the
expression of SOX2 and SOX2OT7 genes are positively cor-
related in lung tumor tissues (R=0.62, P value <0.05).
SOX2 was significantly downregulated
in SOX2OT:siRNA-treated cells
A qRT-PCR approach was utilized to confirm SOX2OT sup-
pression in siRNA-transfected A549 cells. To examine a po-
tential regulatory role of SOX2OT on pluripotency genes’ ex-
pressions, the expression levels of SOX2 and OCT4A genes
were also determined.
Fig. 2 The relative gene expression of lung tumors normalized to paired
normal tissues. a The mean of gene expression alteration is presented for
SOX2, SOX2OT4, SOX2OT7, and OCT4A in tumor tissues. b The gene
expression changes is visualized in different histology of lung cancer
categorized to two adenocarcinoma (AC) and squamous cell carcinoma
(SC) cancer subtypes. The normal tissue expression level is considered as
one. The error bars indicate ±1SE. *p value <0.05
Tumor Biol. (2016) 37:10329–10338 10333
As expected, SOX2OT expression was downregulated
in A549 cells transfected with SOX2OT:siRNA (50 and
100 nM). Interestingly, the expression level of SOX2
was also declined in SOX2OT knockdown cells, in com-
parison to the cells transfected with scrambled siRNA
(Fig. 3b). Our data demonstrated a significant positive
correlation between SOX2OT and SOX2 gene expression
alterations in A549 (R= 0.66, P value = 0.05); however,
the expression level of SOX2OT and OCT4A genes was
not correlated significantly.
SOX2OT suppression revealed its part in proliferation
and colony formation of tumor cells
A potential contribution of SOX2OT in proliferation and col-
ony formation of tumor cel ls were examined in
siRNA:SOX2OT-transfected A549 cell line, for a period of
12 days post-transfection. As it is shown in Fig. 4, SOX2OT
knockdown significantly declined the proliferation rate and
colony size of transfected cells. The colony formation ability
of A549 cells were dramatically declined following SOX2OT
Table 3 The statistics for gene
overexpression in lung tumor
tissues of different histology
Genes Histology Mean Minimum Maximum % samples
with overexpression
SOX2 SCC 7.6200000 2.53000 10.85000 15.78
AC 6.2600000 1.67000 14.80000 31.57
Total 6.7133333 1.67000 14.80000 47
SOX2OT-7 SCC 11.5000000 3.00000 20.00000 10.52
AC 3.6760000 1.30000 8.42000 26.31
Total 5.9114286 1.30000 20.00000 36.8
SOX2OT-4 SCC 10.5150000 1.03000 20.00000 10.52
AC 6.1725000 1.03000 12.59000 21
Total 7.6200000 1.03000 20.00000 31.57
OCT4A SCC 3.5500000 2.64000 4.46000 10.52
AC 6.1725000 1.03000 12.59000 26.31
Total 2.9942857 1.07000 6.10000 36.8
Fig. 3 RNA interference SOX2OT knockdown in A549 cell line. a The
fluorescent microscope image of FITC-siRNA-transfected cells. Green
fluorescent signals indicate the Fluorescein-tagged siRNA in transfected
cells. The non-transfected cell fluorescent microscope image is shown as
a negative control. bThe expression of SOX2OT, SOX2, andOCT4Awere
measured concordantly by relative real-time PCR method. The expres-
sion of SOX2 falls upon SOX2OT knockdown in SOX2OT:siRNA-
transfected cells
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suppression; however, the overall colony numbers were
similar.
SOX2OT has a role in G2/M exit of cell cycle
Cell survival and proliferation are interdependently determin-
ing cancer cell growth. SOX2OT suppression can decrease cell
proliferation either by inhibition of cell proliferation or eleva-
t ion of death rate , or both. For this reason, the
siRNA:SOX2OT-trasfected A549 cells were examined for a
possible alteration in the rate of apoptotic cell death. The flow
cytometry failed to show any significant changes in the num-
ber of annexin V-positive cells, 48 h post-transfection
(Fig. 5a).
Since cell death was not there as on behind the declined
number and size of colonies in siRNA:SOX2OT-transfected
cells, we focused on cell cycle progression of the treated cells
as a probable factor behind the anti-proliferation effect of
SOX2OT suppression. Interestingly, a declined percentage of
the cells in G1 phase of cell cycle were observed in SOX2OT
knocked down A549 cells, which seems to be caused by a
blockage of the cells in G2/M phase of cycle (Fig. 5b).
Declined two-dimensional cell migration in A549 cells
transfected by SOX2OT:siRNA
Considering the vital importance of cell migration in cancer
progression and metastasis, we examined whether the mobil-
ity potential of the lung adenocarcinoma cell line A549 is
affected by SOX2OT knockdown. In this regard, the two-
dimensional motility of siRNA-transfected cells was studied
with a simple wound closure assay. After 24 h, both
concentrations of siRNAs (50 and 100 nM) caused a signifi-
cant decline in cell mobility of SOX2OT knockdown cells,
compared to the cells transfected with scrambled siRNA
(Fig. 6). However, there was no significant difference in mo-
bility of cells treated with different concentration of siRNA.
Discussion
The lncRNAs which make the majority of human tran-
scriptome [27] intercommunicate with cancer pathogenesis
of different tissues [28–30]. A list of lncRNAs expressed dif-
ferently between normal and NSCLC tumor tissue has been
reported, even discriminating squamous cell and adenocarci-
noma sub-types [12, 14]. This indicates the importance of
lncRNA in molecular pathobiology of lung cancer and also
provides new insights in personalized medicine of it.
For example, SCAL1 elevation is an early event in smokers
to protect bronchial airway cells from cigarette smoke side
effects, which may enhance the malignancy [31, 32] and two
another well-known lncRNAs: MALAT1 [33–36] and
HOTAIR [37] are correlated with cancer cell migration and
predict the survival and metastasis of NSCLC.
SOX2OT high expression level is associated with different
cancer tissues of the esophagus [23], breast [21], and lung
[38]. An amplification in 3q26 locus, encompassing SOX2
and SOX2OT, is reported as a common features of squamous
cell carcinoma of lung cancer [17].
Previously, Hou Z et al. reported that SOX2OT upregula-
tion (>2 folds) in lung tumor tissues (53 %) is associated with
poor prognosis. Here, for the first time, we elucidated the
preferential expression of different non-coding SOX2OT-
Fig. 4 The colony formation assay of SOX2OT knockdown and control
cells. The bar chart describes the count of >1- or ∼1-mm colonies in
SOX2OT or control siRNA-transfected A549 cells (a). Crystal violate
stained colony images (b) are presented macroscopically (right column)
and microscopically (×40 magnification, left column). The arrow points
to a typical >1-mm colony and arrow head shows a ∼1-mm one
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spliced transcripts in lung tumors with exon junction specific
primers. Our finding demonstrated over six folds upregulation
of SOX2OT transcript variants 4 and 7 in >30 % of lung tumor
samples compared to normal tissues. Similarly, we found that
the magnitude of expression amplification of both SOX2OTs
was more considerable in squamous cell carcinoma type of
tumors that is concordant with Hou Z et al. report.
Because the SOX2OT encompasses SOX2 gene [39] and
the evidence of concordant SOX2 expression with SOX2OT
during stem cell differentiation and carcinogenesis, it has been
Fig. 6 SOX2OT knockdown effect on A549 wound closure ability. Cells
were transfected with control siRNA or SOX2OT:siRNA (50 and
100 nM). The cells were imaged at 0 and 24 h after scratching. The
wound edges were delimited by black lines and the wound area was
measured for each field; then, the percent of wound closure was
calculated
Fig. 5 The apoptosis (a) and cell cycle progression (b) of SOX2OT
knocked down lung cancer cell line. The A549 cells were transfected
with control and SOX2OT: siRNA (50 and 100 nM), and then were
stained with annexin V/PI for apoptosis evaluation (a). As is shown, no
annexinV-positive cells were detected. The percentage of necrotic cell (PI
positive in top left) is shown in graphs. The flow cytometry evaluation of
PI-stained cell cycle progression is illustrated in right (b). The percentage
of cell population in each cell cycle phase is summarized for each
treatment
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supposed that SOX2OT function is probably related to SOX2
[18, 21, 23, 25]. In this study, we observed a significant cor-
relation between SOX2 and SOX2OT in lung tumor tissues and
siRNA-treated cells which highlights the potential relevance
of these two overlapping genes.
It has been reported that SOX2OT knockdown leads to G2/
M arrest and proliferation inhibition in HCC827 and SKMES-
1 lung cancer cell lines in a EZH2 poly comb protein-
dependent manner [38]. We found similar SOX2OT knock-
down derived antiproliferative and cell cycle effect in A549
adenocarcinoma cancer cell line. An inhibitory function for
SOX2OT suppression in hepatocellular carcinoma cell lines
migration and invasion was reported previously [24]. In the
current study, similar potential function for SOX2OT in A549
cell line migration was recorded. Although RNA interference
[23, 25] and overexpression [21] analysis demonstrated that
SOX2OT function is important in cancer cell, its exact func-
tion still remains to be investigated in detail.
In conclusion, the overexpression of SOX2OT transcript
variants 4 and 7 in lung tumor tissues and its function in
colony formation and proliferation of A549 cell line indicates
the association of this long non-coding RNAwith carcinogen-
esis and progression of non-small cell lung cancer. More in-
vestigation on SOX2OT function indeed will promote our
knowledge on the molecular events happening during non-
small cell lung tumor genesis and progression.
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